Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 3Genitourinary 2Tumor-Agnostic 1Lymphoid 1CNS 1

Conditions

Prostatic Neoplasms 2Neoplasm Metastasis 1

Interventions

pembrolizumab 182Magnetic Resonance Spectroscopy 161Specimen Handling 134enzalutamide 125Nivolumab 118Gemcitabine 96Docetaxel 92Radiosurgery 91Prednisone 81Androgen Antagonists 81Abiraterone Acetate 79Radiotherapy 75apalutamide 66Cisplatin 65darolutamide 62Ipilimumab 61Biopsy 61abiraterone 57cabozantinib 55Carboplatin 55Leuprolide 52enfortumab vedotin 50Radiation 47Pluvicto 45Standard of Care 44atezolizumab 41Surveys and Questionnaires 38acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37X-Rays 37avelumab 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hormones × Genitourinary × 1 year × Clear all
NCT04134260 2026-05-07

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

NRG Oncology

Phase 3 Recruiting
586 enrolled
Genitourinary

Prostatic Neoplasms

NCT06660862 2026-01-08

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

University of Chicago

Phase 4 Not yet recruiting
80 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡